ARCHIVES

An “insurgency” targets randomized trials, demands access to investigational drugs.

This article is from The Cancer Letter archive.

Vol. 31 No. 31 | August 5, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: NCA to Hear Reports On Outstanding Investigator Awards, Defining QRA, P01 Guidelines, Gallow Work

May 6, 1983

51% Control Rate Achieved In Phase II Trial of Elderly Patients

March 29, 2013

ACS California Division Offers Fellowships For Clinical Research

June 14, 1996

Chemo Combinations Tested In Phase III For Lung Cancer

August 31, 2001

First Round Of Cooperative Group Mergers Falls Short Of NCI’s Stated Goal

February 4, 2011

NIH Financial Plan Slated For Discussion At Dec. 18 Meeting

December 14, 1990